No description available.

No description available.

In recent years, the application of microparticles in different fields including cosmetics, agriculture, pharmaceutics and biomedicine has been widely investigated.In this project, we aimed to improve the preparative methods for chitosan–triphosphate microparticles (Cs/TPP) for perspective application in the fields of cell encapsulation and controlled drug delivery. Prior to the preparation of chitosan-based microparticles, in order to confirm good biocompatibility and reproducibility, protocols have been established for the purification and characterisation of chitosan including the assessment of average molecular weight, protein content and degree of deacetylation.This study then primarily focused on the use of β-glycerophosphate (βGP) as an excipient, which is known to solubilize chitosan at neutral pH, thus allowing the preparation of chitosan microparticles (microspheres and toroidal) via ionotropic gelation under physiological conditions. The preparation of Cs-βGP/TPP microparticles was optimized varying several key process variables (concentration, flow rate, and frequency) and these microparticles were produced with a narrow size distribution (400 – 500 μm, spherical shape) and compared to Cs/TPP controls. The main result was the possibility to perform this process at neutral pH, although we have also demonstrated an improved toughness and cross-linking density of these microspheres as a result of the presence of β-glycerophosphate. Further, we have investigated the application of this method to a toroidal geometry, which provides advantages in terms of better transfer of oxygen and nutrients to any encapsulated materials. Cs/TPP and Cs-βGP/TPP ‘micro-doughnuts’ were also prepared and characterised. This research highlighted the evidence of a higher cross-linking density of these microparticles in comparsion with the spherical ones. In order to optimise the physicochemical characteristics of these microparticles for future applications as biomaterials, the surface of Cs/TPP and Cs-βGP/TPP microparticles was modified through an additional polyelectrolyte complexation with poly (sodium 4- styrene sulphonate) (PSS). The improved toughness and cross-linking density was confirmed by measuring the mechanical properties and solid content which indicated the successful complexation of PSS onto the surface of these microparticles.

No description available.

Philosophiae Doctor - PhD / Tsetse flies are the sole vectors of trypanosomes that cause nagana and sleeping sickness in animals and humans respectively in tropical Africa. Tsetse are unique: both sexes adults are exclusive blood-feeders, females are mated young and give birth to a single mature larva in sheltered habitats per pregnancy. Tsetse use chemoreception to detect and respond to chemical stimuli, helping them to locate hosts, mates, larviposition and resting sites. The detection is facilitated by chemoreceptors expressed on sensory neurons to cause specific responses. Specific molecular factors that mediate these responses are poorly understood in tsetse flies. This study aimed to identify and characterize genes that potentially mediate chemoreception in Glossina morsitans morsitans tsetse flies. These genes included sensory odorant (OR), gustatory (GR), ionotropic (IR), and related genes for odorant-binding (OBP), chemosensory (CSP) and sensory neuron membrane (SNMP) proteins. Synaptic transmission in higher brain sites may involve ionotropic glutamate-gated (iGluR) and metabotropic glutamate-gated (mGluR) receptors. The genes were annotated in G. m. morsitans genome scaffold assembly GMOY1.1 Yale strain using orthologs from D. melanogaster as query via TBLASTX algorithm at e-value below 1e-03. Positive blast hits were seeded as gene constructs in their respective scaffolds, and used as genomic reference onto which female fly-derived RNA sequence reads were mapped using CLC Genomics workbench suite. Seeded gene models were modified using RNA-Seq reads then viewed and re-edited using Artemis genome viewer tool. The genome was iteratively searched using the G. m. morsitans gene model sequences to recover additional similar hit sequences. The gene models were confirmed through comparisons against the NCBI conserved domains database (CDD) and non-redundant Swiss-Prot database. Trans-membrane domains and secretory peptides were predicted using TMHMM and SignalP tools respectively. Putative functions of the genes were confirmed via Blast2GO searches against gene ontology database. Evolutionary relationships amongst and between the genes were established using maximum likelihood estimates using best fitting amino acid model test in MEGA5 suite and PhyML tool. Expression profiles of genes were estimated using the RNA-seq data via CLCGenomics RNA-sequences analysis pipeline. Overall, 46 ORs, 14 GRs, and 19 IRs were identified, of which 21, 6 and 4 were manually identified for ORs, GRs, and IRs respectively. Additionally, 15 iGluRs, 6 mGluRs, 5 CSPs, 15 CD36-like, and 32 OBPs were identified. Six copies of OR genes (GmmOR41-46) were homologous to DmelOr67d, a single copy cis vacenyl acetate (cVA) receptor . Genes whose receptor homologs are associated with responses to CO2, GmmGR1-4, had higher expression profiles from amongst glossina GR genes. Known core-receptor homologs OR1, IR8a, IR25a and IR64a were conserved, and three species-specific divergent IRs (IR10a, IR56b and IR56d) were identified. Homologs of GluRIID, IR93a, and sweet taste receptors (Gr5a and Gr64a) were not identified in the genome. Homolog for LUSH protein, GmmOBP26, and sensory neuron membrane receptors SNMP1 and SNMP2 were conserved in the genome. Results indicate reduced repertoire of the chemosensory genes, and suggest reduced host range of the tsetse flies compared to other Diptera. Genes in multiple copies suggest their prioritization in chemoreception, which in turn may be tied to high specificity in host selection. Genes with high sequence conservation and expression profiles probably relate to their broad expression and utility within the fly nervous system. These results lay foundation for future comparative studies with other insects, provide opportunities for functional studies, and form the basis for re-examining new approaches for improving tsetse control tools and possible drug targets based on chemoreception.

Immunohistochemical studies were conducted to assess the subunits of ionotropic and metabotropic glutamate receptor present in the rostral ventrolateral medulla (RVLM) of the rat. Double labeling the medullary sections with polyclonal GluR1, GluR2/3, GluR4, NMDAR1, NMDAR2A/B, mGluR1α, and mGluR2/3 antiserum and monoclonal tyrosine hydroxylase (TH) antiserum revealed nearly all TH immunoreactive (irTH) cells and many TH-negative neurons were immunoreactive to GluR2/3 (irGluR2/3), NMDAR1 (irNMDAR1), and NMDAR2A/B (irNMDAR2A/B). A few RVLM neurons were immunoreactive to GluR1 (irGluR1) and GluR4 (irGluR4), but they were generally TH-negative. Immunoreactivity to mGluR1α (irmGluR1α) appeared to be localized exclusively to fiber-like elements in the RVLM area. Our results show that neurons in the RVLM, including irTH, are endowed mainly with GluR2/3 and NMDAR1 or NMDAR2A/B ionotropic receptor subunits, and that irmGluR1α splice variant appears to be located on nerve fibers ramifying within the RVLM. Moreover, TH-negative neurons in the RVLM appear to bear similar subunits of ionotropic glutamate receptors.

In controlled release applications a drug is molecularly dispersed in a polymer phase. In the presence of a thermodynamically compatible solvent, swelling occurs and the polymer releases its content to the surrounding medium. The rate of the drug release can be controlled by interfering with the swelling rate of the beads or by influencing diffusion through the viscosity of the polymer. Beads that contain chitosan were prepared through the ionotropic gelation method where tripolyphosphate (TPP) was used as the crosslinking agent. Beads that consisted of 3% w/v isoniazid (lNH) and 5% w/v chitosan were prepared in a 5% w/v TPP solution (pH 8.7) as the primary beads. To improve the drug loading of chitosan isoniazid beads (ClB) the TPP concentration, pH of the TPP solution and the INH concentrations were altered for maximum drug loading. To increase the porosity of the beads of chitosan beads Explotab® (EXPL), Ac-Di-Sol® (ADS) and Vitamin C (VC) were added individually to chitosan solutions at concentrations of 0.1, 0.25 and 0.5% w/v before adding the mixture to the TPP solution. Morphology, swelling and drug loading studies were used to evaluate the different formulations. After these excipients were added individually they were also added in combinations of two excipients respectively and characterised. From the results of the drug loading studies the beads that contained only chitosan and isoniazid showed a percentage drug loading of (43.92%) which is the best of all the beads that were analyzed. The multi excipient combination of Ac-Di-Sol® and Explotab® showed the best swelling capability at both pH levels. Dissolution studies were conducted on all the formu lations over a period of 6 hours (360 minutes) at pH 5.6 and pH 7.4. From the dissolution results it were clear that no chitosan dissolved at both pH values. The dissolution of single pharmaceutical excipient (SPE) and multi pharmaceutical excipient (MPE) formulations can be arranged in the following order: VC/ADS < VC < ADS/EXPL < ADS < VC/EXPL < CIB < EXPL. Explotab® is a potential excipient for enhanced drug release over a wide pH range. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2007.

Controlled release systems aim at achieving a predictable and reproducible drug release profile over a desired time period. These controlled release formulations offer many advantages over conventional dosage forms. These advantages include: reduced dosing intervals, constant drug levels in the blood, increased patient compliance and decreased adverse effects. Complex controlled release formulations such as those with sustained release properties, often require additional steps during the production phase. The cost and economic impact associated with these complex controlled release dosage formulations often outweigh the short term benefits. Thus the development of an economic method to produce controlled release particles is of great importance especially in third world countries. In controlled release formulations the drug is often equally dispersed throughout a polymer matrix. In the presence of a thermodynamically compatible solvent, swelling occurs and the polymer releases its content to the surrounding medium. The rate of drug release can be controlled by interfering with the amount of swelling and rate of diffusion by manipulating the viscosity of the polymer matrix. Chitosan is an ideal candidate for controlled drug delivery through matrix release systems. It is a biodegradable polymer with absorption-enhancing properties. Cross-linking chitosan with different cross-linking agents allow the preparation of beads. Beads are frequently used in controlled release dosage forms as they are very flexible in dosage form development and show various advantages over single unit dosage forms. Because beads disperse freely in the gastrointestinal tract they maximize drug absorption, reduce fluctuation in peak plasma, and minimize potential side effects without lowering drug bio-availability. Chitosan beads and excipient containing chitosan beads were prepared and investigated as possible controlled release formulations. Pyrazinamide was chosen as the model drug. Chitosan beads and excipient containing chitosan beads were prepared by ionotropic gelation in tripolyphosphate. In this study chitosan/pyrazinamide beads containing pharmaceutical excipients (Ascorbic acid, Explotab and Ac-Di-Sol) were produced. The excipients were added individually and in combinations to the chitosadpyrazinamide dispersion and the beads were characterized on the basis of their morphology, solubility, fiability, drug loading capacity and swelling behaviour, as well as drug release (dissolution properties). The drug loading of the pyrazinarnide loaded chitosan beads, was 52.26 % 0.57%. It was noted that the inclusion of excipients in the beads resulted in an increase in drug loading with the combination of Ascorbic acid and Ac-Di-Sol giving the highest drug loading of 67.09 ± 0.22%. It was expected that the addition of the pharmaceutical excipients would lead to a sustained release of pyrazinamide. Dissolutions studies, however, revealed a burst release in both phosphate buffer solution (PBS) pH 5.60 and 7.40 over the first 15 minutes and the curve reached a plateau after 30 minutes. Thus, apparently the inclusion of the pharmaceutical excipients did not contribute to a sustained release of pyrazinamide over the tested period of six hours. In future studies the dissolution time can possibly be extended to a period of 24 hours. It might be possible for the remaining drug (approximately 40%) in the beads to be released over the extended period. Other polymers can also be investigated to control the release of pyrazinamide. Further studies are, however, necessary to investigate this possibility in the future. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2007.

Like most organisms, Drosophila melanogaster can synchronize its physiological and behavioural processes by possessing internal circadian clock that regulates. Naturally fluctuating timing cues, like light and temperature (also known as Zeitgebers), synchronize these endogenous and self‐sustained clocks with external time. In Drosophila, synchronization of the circadian clock by light has been studied in detail, but much less is known about the molecular mechanisms underlying temperature entrainment. Previous data from our lab shows that Nocte, a Chordotonal organ (Ch organ) located protein, is required for normal temperature entrainment in Drosophila. However, neither the function of Nocte in temperature entrainment nor the molecular underlying mechanisms are clear. To address these issues, a proteomics strategy of combing co‐immunoprecipitation and MS/MS sequencing was applied to isolate potential interactors of Nocte. IR25a was one of the most promising candidates, which was later confirmed by behavioural tests using RNA interference: Reducing IR25a expression in Chorgan resulted in abnormal behaviour during temperature cycles, similar to what had been described for Nocte mutant. To further confirm the interaction between Nocte and IR25a, I showed that IR25a physically interacts with Nocte in vivo. Moreover, using an IR25a‐gal4 line, I was able to show that IR25a is expressed in subsets of chordotonal organs (Ch organ) including Johnston's Organs (JO), where Nocte is also highly expressed. These results, along with the behavioural data mentioned above are consistent with the proteomics results and suggest that Nocte and IR25a physically and functionally interact. IR25a mutants were employed to further investigate the function of IR25a in temperature entrainment. First of all, I found that both central and peripheral clocks in wild type flies can be synchronized to temperature cycles with only two degree differences (12h: 12h, 27 °C: 25 °C). In contrast, synchronization of locomotor activity rhythms in the IR25a null mutants to the same temperature cycles and other TC's with 2°C amplitude was eliminated. Under the same conditions, the oscillations of the core clock proteins TIMLESS (TIM) and PERIOD (PER) that normally occur in fly heads were completely abolished inIR25a null mutants, suggesting that IR25a is required for temperature entrainment of peripheral clocks. In the central brain pacemaker neurons, the oscillations of TIM in dorsal and lateral neurons were also affected by the IR25a mutants. On the contrary, IR25a is not required for light entrainment and temperature compensation, suggesting that IR25a is specifically involved in temperature synchronization. Moreover, temperature entrainment of the IR25a null mutants can be partially restored by applying larger temperature intervals (29°C: 25°C) indicating that IR25amay function as amplitude detector independent of absolute temperature values. Finally, neuronal activity in IR25a+ neurons is crucial for the synchronization of circadian clocks to low amplitude temperature cycles. Re‐constitution of functional olfactory receptors required the assembly of IR25a with IR76a and IR76b. Interestingly, IR76a and IR76b are neither required for temperature entrainment at the behavioural level nor expressed in the Ch organs. To check if other potential IRs interacting with IR25a exist, I screened the expression pattern of most divergent IRs using IR‐gal4/UAS‐GFP flies. IR56a was isolated as a potential partner of IR25a because it is also expressed in the femur chordotonal organs. To investigate the function of IR56a in temperature entrainment, I generated a null mutant of IR56a. Surprisingly, this gene is not required for synchronizing clocks to a temperature cycle (27°C: 25°C) at the behavioural level. However, the behavioural and molecular phenotypes of IR56a mutant under different temperature cycles need to be further characterized.

Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2007.